Scarica l'app Stockscreener
5.14
3.21%
0.16
Enanta Pharmaceuticals Inc Borsa (ENTA) Ultime notizie
Petri Dish: A monthly Alzheimer's drug from Biogen; Watertown biotech CEO pay falls 66% - The Business Journals
Enanta Pharmaceuticals (ENTA) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Enanta Pharmaceuticals (ENTA) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Assenagon Asset Management S.A. Raises Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Assenagon Asset Management S.A. Buys 49,050 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat
JPMorgan Chase & Co. Increases Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Bought by Barclays PLC - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Average Target Price from Brokerages - MarketBeat
Enanta stock hits 52-week low at $4.83 amid market challenges - Investing.com Australia
Enanta stock hits 52-week low at $4.83 amid market challenges By Investing.com - Investing.com South Africa
Jane Street Group LLC Has $240,000 Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
ENTA (Enanta Pharmaceuticals) Peter Lynch Fair Value : N/A (As of Jan. 11, 2025) - GuruFocus.com
Enanta stock hits 52-week low at $5.29 amid market challenges - Investing.com Nigeria
Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Purchased by Barclays PLC - Defense World
Geode Capital Management LLC Has $4.95 Million Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
(ENTA) Technical Pivots with Risk Controls - Stock Traders Daily
Enanta stock touches 52-week low at $5.68 amid market challenges - Investing.com Australia
Enanta stock touches 52-week low at $5.68 amid market challenges By Investing.com - Investing.com South Africa
Brokers Issue Forecasts for ENTA Q1 Earnings - Defense World
Equities Analysts Offer Predictions for ENTA Q1 Earnings - MarketBeat
Paxlovid Survives Patent Dispute, Securing Pfizer’s Exclusive Rights - The Africa Logistics
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
FY2029 Earnings Estimate for ENTA Issued By HC Wainwright - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Average PT from Brokerages - MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $18.00 by Analysts at HC Wainwright - Defense World
Equities Analysts Set Expectations for ENTA FY2029 Earnings - MarketBeat
Pfizer prevails in Enanta patent case over Covid-19 drug By Investing.com - Investing.com Nigeria
Enanta Pharmaceuticals stock remains Buy-rated with Phase 2 data driving model revisions - Investing.com Australia
When (ENTA) Moves Investors should Listen - Stock Traders Daily
Pfizer prevails in Enanta patent case over Covid-19 drug - Investing.com India
Pfizer Gets Enanta Patent Voided in Case Over Paxlovid Royalties - Bloomberg Law
Enanta Pharmaceuticals (ENTA) Appeals Court Ruling in Patent Dis - GuruFocus.com
HC Wainwright Cuts Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target to $18.00 - MarketBeat
Enanta to appeal as Pfizer wins Paxlovid patent ruling - MSN
Enanta stock slips as Pfizer wins Paxlovid patent (PFE:NYSE) - Seeking Alpha
Enanta Pharmaceuticals to Appeal Ruling in Patent Infringement Case Against Pfizer - MarketWatch
Enanta Pharma Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
Enanta Loses Key Patent Battle Against Pfizer Over COVID Drug Paxlovid in Court Ruling - StockTitan
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last? - Yahoo Finance
Fmr LLC Purchases 7,839 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 27,597 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Charles Schwab Investment Management Inc. Sells 1,649 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):